Evidence map›Paper›PMID 27413707›Full record

ArticleTranslational lung cancer research2016

Prognostic value of lymph node ratio in patients with pathological N1 non-small cell lung cancer: a systematic review with meta-analysis.

Qian Li, Ping Zhan, Dongmei Yuan, Tangfeng Lv, Alexander Sasha Krupnick, Antonio Passaro, Alessandro Brunelli, Matthew P Smeltzer, Raymond U Osarogiagbon, Yong Song

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Overview of Challenges and Opportunities in Revising the Nodal Classification of Lung Cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023
    Review
  4. Article
  5. Article
  6. Article
  7. The surgeon thunderbolts in 2016 lung cancer literature.Annals of translational medicine · 2018
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qian Li1 Department of Respiratory and Critical Care Medicine, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210002, China ; 2 Division of Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, USA ; 3 Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy ; 4 Department of Thoracic Surgery, St. James's University Hospital in Leeds, UK ; 5 School of Public Health, University of Memphis, Memphis, TN, USA ; 6 Thoracic Oncology Research Group, Baptist Cancer Center, Memphis, TN, USA.
Ping Zhan1 Department of Respiratory and Critical Care Medicine, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210002, China ; 2 Division of Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, USA ; 3 Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy ; 4 Department of Thoracic Surgery, St. James's University Hospital in Leeds, UK ; 5 School of Public Health, University of Memphis, Memphis, TN, USA ; 6 Thoracic Oncology Research Group, Baptist Cancer Center, Memphis, TN, USA.
Dongmei Yuan1 Department of Respiratory and Critical Care Medicine, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210002, China ; 2 Division of Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, USA ; 3 Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy ; 4 Department of Thoracic Surgery, St. James's University Hospital in Leeds, UK ; 5 School of Public Health, University of Memphis, Memphis, TN, USA ; 6 Thoracic Oncology Research Group, Baptist Cancer Center, Memphis, TN, USA.
Tangfeng Lv1 Department of Respiratory and Critical Care Medicine, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210002, China ; 2 Division of Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, USA ; 3 Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy ; 4 Department of Thoracic Surgery, St. James's University Hospital in Leeds, UK ; 5 School of Public Health, University of Memphis, Memphis, TN, USA ; 6 Thoracic Oncology Research Group, Baptist Cancer Center, Memphis, TN, USA.
Alexander Sasha Krupnick1 Department of Respiratory and Critical Care Medicine, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210002, China ; 2 Division of Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, USA ; 3 Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy ; 4 Department of Thoracic Surgery, St. James's University Hospital in Leeds, UK ; 5 School of Public Health, University of Memphis, Memphis, TN, USA ; 6 Thoracic Oncology Research Group, Baptist Cancer Center, Memphis, TN, USA.
Antonio Passaro1 Department of Respiratory and Critical Care Medicine, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210002, China ; 2 Division of Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, USA ; 3 Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy ; 4 Department of Thoracic Surgery, St. James's University Hospital in Leeds, UK ; 5 School of Public Health, University of Memphis, Memphis, TN, USA ; 6 Thoracic Oncology Research Group, Baptist Cancer Center, Memphis, TN, USA.
Alessandro Brunelli1 Department of Respiratory and Critical Care Medicine, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210002, China ; 2 Division of Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, USA ; 3 Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy ; 4 Department of Thoracic Surgery, St. James's University Hospital in Leeds, UK ; 5 School of Public Health, University of Memphis, Memphis, TN, USA ; 6 Thoracic Oncology Research Group, Baptist Cancer Center, Memphis, TN, USA.
Matthew P Smeltzer1 Department of Respiratory and Critical Care Medicine, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210002, China ; 2 Division of Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, USA ; 3 Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy ; 4 Department of Thoracic Surgery, St. James's University Hospital in Leeds, UK ; 5 School of Public Health, University of Memphis, Memphis, TN, USA ; 6 Thoracic Oncology Research Group, Baptist Cancer Center, Memphis, TN, USA.
Raymond U Osarogiagbon1 Department of Respiratory and Critical Care Medicine, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210002, China ; 2 Division of Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, USA ; 3 Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy ; 4 Department of Thoracic Surgery, St. James's University Hospital in Leeds, UK ; 5 School of Public Health, University of Memphis, Memphis, TN, USA ; 6 Thoracic Oncology Research Group, Baptist Cancer Center, Memphis, TN, USA.
Yong Song1 Department of Respiratory and Critical Care Medicine, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210002, China ; 2 Division of Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, USA ; 3 Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy ; 4 Department of Thoracic Surgery, St. James's University Hospital in Leeds, UK ; 5 School of Public Health, University of Memphis, Memphis, TN, USA ; 6 Thoracic Oncology Research Group, Baptist Cancer Center, Memphis, TN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-small cell lung cancer (NSCLC) patients with N1 disease have variable outcomes, and additional prognostic factors are needed. The number of positive lymph nodes (LNs) has been proposed as a prognostic indicator. However, the number of positive LNs depends on the number of LNs examined from the resection specimen. The lymph node ratio (LNR) can circumvent this limitation. The purpose of this study is to evaluate LNR as a predictor of survival and recurrence in patients with pathologic N1 NSCLC.

methodsWe systematically reviewed studies published before March 17, 2016, on the prognostic value of LNR in patients with pathologic N1 NSCLC. The hazard ratios (HRs) and their 95% confidence intervals (CIs) were used to combine the data. We also evaluated heterogeneity and publication bias.

resultsFive studies published between 2010 and 2014 were eligible for this systematic review with meta-analysis. The total number of patients included was 6,130 ranging from 75 to 4,004 patients per study. The combined HR for all eligible studies evaluating the overall survival (OS) and disease-free survival (DFS) of N1 LNR in patients with pathologic N1 NSCLC was 1.53 (95% CI: 1.22-1.85) and 1.64 (95% CI: 1.19-2.09), respectively. We found no heterogeneity and publication bias between the reports.

conclusionsLNR is a worthy predictor of survival and cancer recurrence in patients with pathological N1 NSCLC.

Indexed as

Lymph node ratio (LNR)N1 node, meta-analysisnon-small cell lung cancer (NSCLC)

Identifiers

PMID27413707
PMCPMC4931126

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.